化依米达佐皮拉基结核素聚合抑制剂抑制神经母细胞瘤细胞功能
Joshua Thammathong1, Kaylee B Chisam2, Garrett E Tessmer2
1Department of Chemistry, Middle Tennessee State University, Murfreesboro, Tennessee 37132, United States.
ACS medicinal chemistry letters
|September 22, 2023
概括
研究人员开发了新的化伊米达索皮里丁和-皮拉化合物,作为用于癌症治疗的菌素结合部位抑制剂 (CBSI). 伊米达佐[1,2-a]皮拉系列显示对神经母细胞瘤的疗效,平衡功效和代谢稳定性.
科学领域:
- 药用化学 医学化学
- 癌症生物学 癌症生物学
- 分子药理学分子药理学
背景情况:
- 向图布林的菌素结合部位提供了一种策略,以克服现有的图布林聚合抑制剂的局限性.
- 开发新型的胆固醇结合部位抑制剂 (CBSI) 在平衡代谢稳定性和细胞功效方面面临挑战.
研究的目的:
- 设计,合成和评估新型的化伊米达索皮里丁和-皮拉CBSI.
- 评估这些新型化合物的细胞活性,代谢稳定性和素结合特性.
主要方法:
- 新型化伊米达索皮里丁和-皮拉衍生物的合成.
- 对癌症细胞系的细胞活动的评估,包括具有MYCN放大细胞系的细胞系.
- 评估代谢稳定性和氨酸结合特性.
主要成果:
- 伊米达佐[1,2-a]皮拉系列证明了对神经母细胞瘤细胞系与MYCN放大功能的有效性.
- 含有伊米达佐[1,2-a]pyrazine核心和trimethoxyphenyl环D的化合物表现出优越的细胞活性和结合.
- 二甲基或二甲基环D替代物增强了新陈代谢稳定性,尽管强度有所降低.
结论:
- 新的化伊米达索皮里丁和-皮拉衍生物显示出作为CBSI的前景.
- 伊米达佐[1,2-a]皮拉津支架对特定的神经母细胞瘤亚型有效.
- 结构性修改可以调节CBSI中代谢稳定性和细胞功率之间的平衡.
相关概念视频
Drugs that Stabilize Microtubules
2.1K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K
Drugs that Destabilize Microtubules
2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Destabilization of Microtubules
2.8K
The destabilization of microtubules can occur during different stages of the microtubule lifecycle, such as nucleation or elongation. It can take place at either end of the microtubule or in the microtubule lattices as a whole. The lifespan of individual microtubules within a cell varies according to the cell type and stage of the cell cycle. During interphase, the lifespan of the microtubule is about 30 minutes, while during cell division, it is about 15 minutes. In axonal microtubules of...
2.8K


